Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
developed in both oral and subcutaneous forms for metabolic disorders such as obesity, while also progressing two large Phase 3 trials in obesity and type 2 diabetes. Alongside this clinical milestone, the company hired experienced cardiometabolic commercial leader Neil Aubuchon as chief commercial officer, signaling a clear focus on preparing VK2735 and its broader metabolic pipeline for potential commercialization. We'll now examine how the completion of VK2735's maintenance study and new commercial leadership may influence Viking Therapeutics' investment narrative. Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave To own Viking Therapeutics today, you have to believe VK2735 can ultimately become a meaningful player in the GLP-1/GIP obesity and diabetes market despite fierce, well-funded incumbents. The newly completed maintenance dosing study and ongoing Phase 3 programs keep clinical execution at the center of the story, w
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPR Newswire
- What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]Yahoo! Finance
- VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug [Yahoo! Finance]Yahoo! Finance
- Lightning Round: QXO is a buy, says Jim Cramer [CNBC]CNBC
- Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- VKTX's page on the SEC website